VGF-derived peptide; spans residues 556-576 of the precursor sequence. Protects cerebellar granule cells (CGCs) from serum and potassium deprivation-induced apoptosis. Increases energy expenditure and prevents early phase diet-induced diabetes.
|Storage||Desiccate at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solubility||Soluble to 1 mg/ml in water|
Preparing Stock Solutions
The following data is based on the product molecular weight 2432.77. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||0.41 mL||2.06 mL||4.11 mL|
|5 mM||0.08 mL||0.41 mL||0.82 mL|
|10 mM||0.04 mL||0.21 mL||0.41 mL|
|50 mM||0.01 mL||0.04 mL||0.08 mL|
References are publications that support the biological activity of the product.
Severini et al (2008) TLQP-21, a neuroendocrine VGF-derived peptide, prevents cerebellar granule cell death induced by serum and potassium deprivation. J.Neurochem. 104 534 PMID: 18173805
Bartolomucci et al (2006) TLQP-21, a VGF-derived peptide, increases energy expenditure and prevents the early phase of diet-induced obesity. Proc.Natl.Acad.Sci. USA 103 14584
Jethwa et al (2007) VGF-derived peptide, TLQP-21, regulates food intake and body weight in Siberian hamsters. Endocrinol. 148 4044
If you know of a relevant reference for TLQP 21, please let us know.
View Related Products by Target
Keywords: TLQP 21, TLQP 21 supplier, VGF-derived, peptide, Neurotrophin, Receptors, TLQP21, Other, Apoptosis, Trk, 3051, Tocris Bioscience
1 Citation for TLQP 21
Citations are publications that use Tocris products. Selected citations for TLQP 21 include:
Hannedouche et al (2013) Identification of the C3a receptor (C3AR1) as the target of the VGF-derived peptide TLQP-21 in rodent cells. Front Pharmacol 288 27434 PMID: 23940034
Do you know of a great paper that uses TLQP 21 from Tocris? Please let us know.
Reviews for TLQP 21
There are currently no reviews for this product. Be the first to review TLQP 21 and earn rewards!
Have you used TLQP 21?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's Disease Poster
Huntington's disease (HD) is a monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the MSN intracellular signaling pathways implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.